Biocon Biologics and Civica partner to expand U.S. Insulin Aspart access

Civica, a non-profit generic drug and pharmaceutical company established in 2018 to address and resolve life-saving drug shortages and affordability, and Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, announced a strategic collaboration agreement to increase Insulin Aspart's accessibility and affordability in the US.

The agreement states that Civica, Inc. will employ the Insulin Aspart drug substance that Biocon Biologics will provide to create the Insulin Aspart drug product, a rapid-acting insulin analog, in its Petersburg, Virginia, production plant.  Following the conclusion of clinical testing and development work, Civica will bring the medication to the American market.  No technology transfer is involved in the agreement.

 "As a fully integrated global biologics company, Biocon Biologics is uniquely positioned to drive commercial success through tailored go-to-market strategies that create lasting value for all stakeholders. Our collaboration with Civica reflects this commitment, enabling us to expand patient access to Insulin Aspart in the United States while reinforcing our dedication to serving the growing needs of people living with diabetes. Together, we are working to ensure more patients have access to high-quality, affordable insulin," said Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd.

The joint venture supports ongoing assessment by the FDA for Biocon Biologics' Insulin Aspart Drug Product to reach the United States market. A diagnosis remains undetected in 11.6 percent of Americans who have diabetes, constituting 38.4 million individuals. Data shows that prediabetes exists in 97.6 million American patients who have received their medical diagnosis.